ReviewSensors (Basel, Switzerland)2025
Nanomaterial-Mediated Electrochemical and Optical Biosensors and Their Application in Tumour Marker Detection.
Review in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.Journal of cancer research and clinical oncology · 2026Review
- Recent Advances on Sensor Technologies for the Monitoring of Tumor Markers.Molecules (Basel, Switzerland) · 2026Review
- Nanobiosensors for Rheumatoid Arthritis Biomarkers: Advances and Clinical Translational Potential.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer constitutes a category of diseases with high mortality rates, where early and precise detection plays a crucial role in diagnosis and treatment. Tumour markers are biomolecules produced during cancer progression, predominantly inert molecules that prove difficult to detect at low concentrations. Traditional detection methods, however, exhibit shortcomings in sensitivity and convenience. Biosensors, with their portability and high sensitivity, hold broad application prospects for detecting tumour markers. Nanomaterials, enhancing detection performance through signal amplification mechanisms, have increasingly become the primary choice for improving sensor analytical capabilities. This review retrieved 60 relevant publications from the Web of Science and PubMed databases (2018-2024) covering "nanomaterials, biosensors, tumour markers", focusing on those employing signal amplification mechanisms and providing clinical sample validation. It summarises signal amplification mechanisms in nanomaterial-mediated electrochemical and optical biosensors, contrasting the differences between these two sensor types. This review focuses on the relationship between "nanomaterial functionality, signal amplification, and clinical application". It systematises and presents the latest advances in nanomaterial-mediated biosensors for detecting tumour markers, analysing the challenges encountered in their clinical implementation. While providing guidance for the clinical translation of nanomaterial-mediated biosensors from laboratory research, their practical application still requires validation through further multicentre, large-scale studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.